Loading...
XNAS
TKNO
Market cap276mUSD
Jul 09, Last price  
5.42USD
1D
5.24%
1Q
92.20%
IPO
-80.63%
Name

Alpha Teknova Inc

Chart & Performance

D1W1MN
XNAS:TKNO chart
P/E
P/S
7.17
EPS
Div Yield, %
Shrs. gr., 5y
68.17%
Rev. gr., 5y
5.30%
Revenues
41m
+7.35%
20,094,00031,297,00036,893,00041,420,00036,684,00037,745,00040,520,000
Net income
-17m
L-35.47%
-1,305,0003,570,000-9,803,000-47,468,000-36,780,000-26,745,000-17,259,000
CFO
-9m
L-30.22%
2,172,0002,505,000-9,069,000-27,400,000-18,814,000-12,391,000-8,646,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Alpha Teknova, Inc. supplies vital scientific reagents to the life sciences sector across both the United States and international markets. These crucial materials play a key role in facilitating the exploration, evolution, and ultimate production of biopharmaceutical goods, such as advanced drug treatments, new vaccines, and molecular diagnostic solutions. The company's product offerings encompass pre-filled media plates designed for cell growth and replication; liquid cell culture media and complementary supplements that promote cellular proliferation; and various molecular biology reagents used for the handling, rehydration, and purification of samples. Teknova caters to a diverse clientele within the life sciences arena, including pharmaceutical companies, biotechnology firms, contract development and manufacturing organizations (CDMOs), in vitro diagnostic businesses, and academic and governmental research facilities. Founded in 1996, Alpha Teknova's main office is situated in Hollister, California.
IPO date
Jun 25, 2021
Employees
285
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT